Eldricare

eldricare.com

EldriCare is a population health management company that combines innovative technology with outstanding care management services. We make a difference in people’s lives by effectively engaging them to improve their health. Our expert care teams leverage predictive analytics, the most advanced care management platform in the world, and patient engagement technology to guide, impact, and personalize the care experience.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

news image

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More

PHYLAGEN, A BIOTECH COMPANY LAUNCHES PHYLAGEN SURFACE™ SARS-COV-2 TEST KIT TO DETECT THE VIRUS

Phylagen | July 31, 2020

news image

Phylagen, an award-winning biotech company specializing in decoding the environmental microbiome for indoor safety, today announced the national availability of its Phylagen Surface™ SARS-CoV-2 (COVID-19) test kit. Designed to be used by anyone on any surface, Phylagen Surface™ provides an early indication of outbreaks in shared spaces including nursing homes, schools, hospitals, restaurants, offices and retail shops."Surface testing can help curb the spread of COVID-19 bu...

Read More

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

news image

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More

Medical

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

news image

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More
news image

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More
news image

PHYLAGEN, A BIOTECH COMPANY LAUNCHES PHYLAGEN SURFACE™ SARS-COV-2 TEST KIT TO DETECT THE VIRUS

Phylagen | July 31, 2020

Phylagen, an award-winning biotech company specializing in decoding the environmental microbiome for indoor safety, today announced the national availability of its Phylagen Surface™ SARS-CoV-2 (COVID-19) test kit. Designed to be used by anyone on any surface, Phylagen Surface™ provides an early indication of outbreaks in shared spaces including nursing homes, schools, hospitals, restaurants, offices and retail shops."Surface testing can help curb the spread of COVID-19 bu...

Read More
news image

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More
news image

Medical

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us